Exploring the path to selective TRK inhibition

About Us

At Loxo Oncology, our mission is to translate scientific knowledge about the drivers of cancer into drugs that can provide substantial benefits for patients


Loxo Oncology is focused on developing highly selective medicines for patients with genetically defined cancers.


We believe that it is these drivers upon which cancers are dependent for their survival and that medicines built to specifically address these drivers have high probability of inhibiting the affected oncogenic pathway.


Loxo Oncology is developing medicines for well-defined patient populations whose cancers share common drivers.


By designing highly selective medicines, we believe there is the potential to deliver treatments that increase clinical benefit of treatment in patients with genetically defined cancers and to fulfill a promise of precision medicine for appropriate patients.

Loxo Oncology develops highly selective medicines with the potential to deliver clinical responses for patients with genetically defined cancers.

Learn More About Loxo

Loxo Oncology is exploring a path to selective inhibition of TRK with larotrectinib (LOXO-101), a targeted cancer therapeutic for tropomyosin receptor kinase (TRK) genetic alterations, focused initially on patients with TRK fusions.

LOXO-101 Trials